Metastatic Castration-Sensitive Prostate Cancer Market to Reach Upto USD 5.5 billion by 2032 | DelveInsight
Metastatic Castration-Sensitive Prostate Cancer market dynamics is anticipated to witness a significant growth owing to the rising prevalence of prostate cancer cases due to the rapidly aging population growing awareness among people, market penetration in mCSPC due to label expansion, and entry of new emerging therapies.
LAS VEGAS, June 20, 2022 /PRNewswire/ -- DelveInsight's Metastatic Castration-Sensitive Prostate Cancer Market Insights report proffers a detailed comprehension of the Metastatic Castration-Sensitive Prostate Cancer Market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Metastatic Castration-Sensitive Prostate Cancer Market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of the salient features from the Metastatic Castration-Sensitive Prostate Cancer Market Report:
- The Metastatic Castration-Sensitive Prostate Cancer market size in the 7MM was valued at USD 679.1 million in 2021 and is anticipated to grow during the study period (2019-2032).
- Key pharmaceutical Metastatic Castration-Sensitive Prostate Cancer companies such as Astellas Pharma, Pfizer, Janssen Pharmaceutical, Myovant Sciences, Takeda, Bayer, Merck Sharp & Dohme, Clovis Oncology, Bristol-Myers Squibb, Novartis Pharmaceuticals, Ferring Pharmaceuticals, Genentech, Exelixis, AstraZeneca, and others are reported to bring a significant shift in the Metastatic Castration-Sensitive Prostate Cancer Market.
- The Metastatic Castration-Sensitive Prostate Cancer emerging therapies that are expected to launch in the forecast period include Talazoparib, Nubeqa, Keytruda, Niraparib, Rubraca, Opdivo (nivolumab), Capivasertib, 177Lu-PSMA-617, Firmagon (Degarelix), Tecentriq (Atezolizumab), Cabometyx (Cabozantinib), and others.
- The United States accounts for the largest Metastatic Castration-Sensitive Prostate Cancer market size when compared to EU5 and Japan. In the United States, the Metastatic Castration-Sensitive Prostate Cancer market size was valued at USD 502.7 million in 2021 and is anticipated to rise during the forecast period.
- Earlier, most of the attention in the field of advanced prostate cancer was restricted to the research and development of drugs for patients with CRPC even though CSPC is burdened with poor prognosis and impaired quality of life. However, recent years have witnessed an expansion in the field of mCSPC which led to the FDA approval of a handful of drugs for this patient pool. Owing to these approvals, the market poses an opportunity for the upcoming drugs. Any medication, if approved, may capture a major share of the market due to a less competitive scenario.
For further information on the market impact by therapies, download the Metastatic Castration-Sensitive Prostate Cancer Market sample @ Metastatic Castration-Sensitive Prostate Cancer Therapeutic Scenario
Metastatic Castration-Sensitive Prostate Cancer Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rd most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives. Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. Prostate cancer treatment includes mainly hormonal therapies (also known as androgen-deprivation therapy or ADT), chemotherapy, immunotherapy, radiation therapy, and surgery. For localized or locally advanced prostate cancer active surveillance, surgery, and radiation therapy are the 3 major treatment options. Patients who have never received ADT i.e. are sensitive to ADT are known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). For many years, the mCSPC market lacked treatment choices. While ADT produces early responses, progression is common, and men who are diagnosed with metastatic illness for the first time account for a high proportion of prostate cancer-related death. Due to advancements in clinical researcher for mCSPC, we now know that, in addition to ADT alone, adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to ADT early on increases overall survival considerably.
Metastatic Castration-Sensitive Prostate Cancer Epidemiology Segmentation
As per DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets was 7,726,394 cases in 2021. The cases in the 7MM are expected to increase during the study period, i.e., 2019–2032.
As per DelveInsight estimates, the diagnosed cases of prostate cancer were the highest in the United States. The diagnosed cases of Prostate cancer in 2021 in the US were 1,327,642 cases.
The Metastatic Castration-Sensitive Prostate Cancer Market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into
- Total Prevalent Cases of Prostate Cancer
- Total Diagnosed Cases of Prostate Cancer
- Age-specific Cases of Prostate Cancer
- Total Diagnosed Cases of Prostate Cancer
- Total Metastatic Cases of Castration-Sensitive Prostate Cancer
- Total Treated Cases of Metastatic Castration-Sensitive Prostate Cancer
Keen to learn how Metastatic Castration-Sensitive Prostate Cancer Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ Metastatic Castration-Sensitive Prostate Cancer Epidemiological Insights
Metastatic Castration-Sensitive Prostate Cancer Market Outlook
From the past few years, improvements in the field of prostate cancer have shown that treatments are more effective when used early. However, combination therapy has yet to be proven beneficial. In order to achieve that, it is necessary to possess a profound understanding of the Metastatic Castration-Sensitive Prostate Cancer market, and the associated unmet needs. Reflecting on these issues, the significance of dedicating resources to R&D is also imperative. Moreover, to achieve significant success in Metastatic Castration-Sensitive Prostate Cancer pricing, policies must be considered, because this further will help in the launch of a product that is truly attractive and appropriate to the market, where it is launched. All these factors help in building a strong product-market fit.
Metastatic Castration-Sensitive Prostate Cancer treatment includes Zytiga (in combination with prednisone) manufactured by Janssen Pharmaceutical and was FDA approved in 2018. Another drug from Janssen that was approved in September 2019 was Erleada. And then, in December 2019, the FDA approved Xtandi for Metastatic Castration-Sensitive Prostate Cancer patients manufactured by the pharma giant - Pfizer. Lastly, in December 2020, Orgovyx by Myovant Sciences bagged FDA approval.
The dynamics of the Metastatic Castration-Sensitive Prostate Cancer (mCSPC) market is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. The launch of emerging therapies is expected during the forecast period of 2022–2032. Potential Metastatic Castration-Sensitive Prostate Cancer therapies expected to launch are as follows Bayer (Nubeqa), Merck Sharp & Dohme, (Keytruda/), Pfizer (Talazoparib), Janssen (Niraparib), Clovis Oncology (Rubraca), Bristol-Myers Squibb (Opdivo), AstraZeneca (Capivasertib), Novartis (177Lu-PSMA-617), and others.
Discover more about therapy set to grab substantial Metastatic Castration-Sensitive Prostate Cancer Market share @ Metastatic Castration-Sensitive Prostate Cancer Market Landscape
Metastatic Castration-Sensitive Prostate Cancer Pipeline Therapies and Key Companies
- Nubeqa: Bayer
- Keytruda: Merck Sharp & Dohme
- Talazoparib: Pfizer
- Niraparib: Janssen
- Rubraca: Clovis Oncology
- Opdivo: Bristol-Myers Squibb
- Capivasertib: AstraZeneca
- 177Lu-PSMA-617: Novartis
- Tecentriq: Genentech
- Firmagon: Ferring Pharmaceuticals
- Cabometyx: Exelixis/ Bristol-Myers Squibb
To know about more pipeline therapies covered in the report, visit @ Metastatic Castration-Sensitive Prostate Cancer Pipeline Analysis, Clinical Trials, and Emerging Therapies
Metastatic Castration-Sensitive Prostate Cancer Market Dynamics
Metastatic Castration-Sensitive Prostate Cancer market growth in the coming years is dependent on several factors such as increasing initiatives for R&D, a surge in investigation regarding prostate cancer treatment products. Also, innovation in drugs and developments in genomics and proteomics, as well as label expansion within prostate cancer, will directly boost the Metastatic Castration-Sensitive Prostate Cancer market. The increase in awareness regarding the disease is also considered an aspect driving the Metastatic Castration-Sensitive Prostate Cancer market growth.
On the other hand, factors such as the emergence of generics, the need for novel therapies, and poor prognosis may serve as obstructions in the Metastatic Castration-Sensitive Prostate Cancer market growth. The complex issue of companion diagnostics, cost constraints observed and the issue of entry barriers might act as potential setbacks in the Metastatic Castration-Sensitive Prostate Cancer market.
Know which therapy is expected to score the touchdown first @ Metastatic Castration-Sensitive Prostate Cancer Market Landscape and Forecast
Scope of the Metastatic Castration-Sensitive Prostate Cancer Market Report
- Study Period: 2019-32
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Metastatic Castration-Sensitive Prostate Cancer Companies: Astellas Pharma, Pfizer, Janssen Pharmaceutical, Myovant Sciences, Takeda, Bayer, Merck Sharp & Dohme, Clovis Oncology, Bristol-Myers Squibb, Novartis Pharmaceuticals, Ferring Pharmaceuticals, Genentech, Exelixis, AstraZeneca
- Key Metastatic Castration-Sensitive Prostate Cancer Pipeline Therapies: Talazoparib, Nubeqa, Keytruda, Niraparib, Rubraca, Opdivo (nivolumab), Capivasertib, 177Lu-PSMA-617, Firmagon (Degarelix), Tecentriq (Atezolizumab), Cabometyx (Cabozantinib)
- Metastatic Castration-Sensitive Prostate Cancer Therapeutic Assessment: Metastatic Castration-Sensitive Prostate Cancer current marketed and emerging therapies
- Metastatic Castration-Sensitive Prostate Cancer Market Dynamics: Metastatic Castration-Sensitive Prostate Cancer Market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs
- KOL's views
- Analyst's views
- Metastatic Castration-Sensitive Prostate Cancer Market Access and Reimbursement
Request for a Webex demo of the report @ Metastatic Castration-Sensitive Prostate Cancer Therapeutics Market
Table of Contents
1 |
Key Insights |
2 |
Report Introduction |
3 |
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Overview at a Glance |
3.1 |
Market Share (%) Distribution of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in 2020 |
3.2 |
Market Share (%) Distribution of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in 2030 |
4 |
Executive Summary of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
5 |
Key Events |
6 |
Epidemiology and Market Forecast Methodology |
7 |
SWOT Analysis |
8 |
Disease Background and Overview |
8.1.1 |
Signs and Symptoms of Prostate Cancer |
8.1.2 |
Risk Factors and Causes of Prostate Cancer |
8.1.3 |
Pathophysiology of Prostate Cancer |
8.1.4 |
Prostate Neoplasia |
8.1.5 |
Genetics of Prostate Cancer |
9 |
Diagnosis of Prostate Cancer |
9.1.1 |
Screening Tests for Prostate Cancer |
9.1.2 |
Tests to Diagnose Prostate Cancer |
9.1.3 |
Stages and Grades of Prostate Cancer |
10 |
Treatment and Management of Prostate Cancer |
10.1 |
Treatment Algorithm of Prostate Cancer |
10.2 |
Observation or Active Surveillance |
10.3 |
Surgery |
10.3.1 |
Open or Laparoscopic Radical Prostatectomy |
10.3.2 |
Risks of Prostate Surgery |
10.4 |
Radiation Therapy |
10.4.1 |
Types of Radiation Therapy |
10.5 |
Hormone Therapy |
10.5.1 |
Types of Hormone Therapy |
10.6 |
Immunotherapy |
10.6.1 |
Vaccine |
10.6.2 |
Immune checkpoint inhibitors |
10.7 |
Chemotherapy |
11 |
American Urological Association (AUA) Guidelines for mHSPC: 2020 |
12 |
Guidelines for mHSPC: Abiraterone acetate combined with castration is another standard (European Association of Urology, 2018) |
13 |
National Institute for health and care excellence (NICE) Recommendation Guidelines for mCSPC/mHSPC: 2022 |
14 |
SEOM Clinical Guidelines for mCSPC/mHNPC: 2021 |
15 |
Updated NCCN Guidelines for mCSPC |
16 |
Epidemiology and Patient Population |
16.1 |
Key Findings |
16.2 |
Total Prevalent Cases of Prostate Cancer in the 7MM |
16.3 |
Total Diagnosed Cases of Prostate Cancer in the 7MM |
16.4 |
Total Metastatic Cases of CSPC/HSPC in the 7MM |
16.5 |
Total Treated Cases of Metastatic CSPC/HSPC in the 7MM |
16.6 |
Assumptions and Rationale |
16.7 |
The United States |
16.7.1 |
Total Diagnosed Cases of Prostate Cancer in the United States |
16.7.2 |
Age-specific Cases of Prostate Cancer in the United States |
16.7.3 |
Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States |
16.7.4 |
Total Metastatic Cases of CSPC/HSPC in the United States |
16.7.5 |
Total Treated Cases of Metastatic CSPC/HSPC in the United States |
16.8 EU-5 Epidemiology |
|
16.8.1 |
Total Diagnosed Prevalent cases of Prostate Cancer in EU5 |
16.8.2 |
Age-specific Diagnosed Prevalent Cases of Prostate Cancer in EU5 |
16.8.3 |
Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in EU5 |
16.8.4 |
Total Metastatic Cases of CSPC/HSPC in EU5 |
16.8.5 |
Total Treated Cases of Metastatic CSPC/HSPC in EU5 |
16.9 Japan |
87 |
16.9.1 |
Total Diagnosed Prevalent cases of Prostate Cancer in Japan |
16.9.2 |
Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan |
16.9.3 |
Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan |
16.9.4 |
Total Metastatic Cases of CSPC/HSPC in Japan |
16.9.5 |
Total Treated Cases of Metastatic CSPC/HSPC in Japan |
17 |
Organizations contributing towards Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
18 |
Marketed Therapies |
18.1 |
Key Competitors |
18.2 |
Xtandi (enzalutamide): Astellas Pharma/Pfizer |
18.2.1 |
Product Description |
18.2.2 |
Regulatory Milestones |
18.2.3 |
Other Developmental Activities |
18.2.4 |
Clinical Development activity |
18.2.5 |
Safety and Efficacy |
18.3 |
Erleada (apalutamide): Janssen Pharmaceutical |
18.3.1 |
Product Description |
18.3.2 |
Regulatory Milestones |
18.3.3 |
Other Developmental Activities |
18.3.4 |
Clinical Development activity |
18.3.5 |
Safety and Efficacy |
18.4 |
Orgovyx (relugolix): Myovant Sciences/Takeda |
18.4.1 |
Product Description |
18.4.2 |
Regulatory Milestones |
18.4.3 |
Clinical Development activity |
18.4.4 |
Safety and Efficacy |
19 |
Emerging Therapies |
19.1 |
Key Competitors |
19.2 |
Emerging Drugs |
19.2.1 |
Nubeqa (Darolutamide): Bayer |
19.2.2 |
Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme |
19.2.3 |
Talazoparib: Pfizer |
19.2.4 |
Niraparib: Janssen |
19.2.5 |
Rubraca (Rucaparib): Clovis Oncology |
19.2.6 |
Opdivo (Nivolumab): Bristol-Myers Squibb |
19.2.7 |
Capivasertib (AZD 5363): AstraZeneca |
19.2.8 |
177Lu-PSMA-617: Novartis Pharmaceuticals |
19.2.9 |
Firmagon (Degarelix): Ferring Pharmaceuticals |
19.2.10 |
Tecentriq (Atezolizumab): Genentech |
19.2.11 |
Cabometyx (Cabozantinib): Exelixis/ Bristol-Myers Squibb |
20 |
Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Seven Major Market Analysis |
20.1 |
Key Findings |
20.2 |
Total Market Size of MHSPC/mCSPC in the 7MM |
20.3 |
Market Size of MHSPC/mCSPC by therapies in the 7MM |
20.4 |
Market Outlook |
20.5 |
Key Market Forecast Assumptions |
20.6 |
United States Market Size |
20.6.1 |
Total Market Size of mHSPC/mCSPC in the United States |
20.6.2 |
Market Size of MHSPC/mCSPC by Therapies in the United States |
20.7 EU-5 Market Size |
|
20.7.1 |
Total Market size of mHSPC/mCSPC in EU5 |
20.7.2 |
Market Size of mHSPC/mCSPC by Therapies in EU5 |
20.8 Japan |
|
20.8.1 |
Total Market size of mHSPC/mCSPC in Japan |
20.8.2 |
Market Size of mHSPC/mCSPC by Therapies in Japan |
21 |
Market Drivers |
22 |
Market Barriers |
23 |
Unmet Needs |
24 |
Reimbursement and Market Access |
25 |
Appendix |
25.1 |
Bibliography |
26 |
Report Methodology |
27 |
DelveInsight Capabilities |
28 |
Disclaimer |
29 |
About DelveInsight |
Get in touch with our Business executive @ Metastatic Castration-Sensitive Prostate Cancer Regulatory and Patent Analysis
Related Reports
DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like Bayer Health Care, Amgen, Janssen Pharmaceutical, Sanofi, AstraZeneca/ Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hoffmann-La Roche, Pfizer, Clovis Oncology, Regeneron Pharmaceuticals, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.
DelveInsight's, "CAR-T – Pipeline Insights, 2021," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd. and others.
Acute Myeloid Leukemia Pipeline
DelveInsight's, "Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including BioSight, GlycoMimetics, Novartis, Takeda, Menarini Group, ImmunoGen, Kartos Therapeutics, Plexxikon, Shijiazhuang Yiling Pharmaceutical, JW Pharmaceutical, Hanmi Pharmaceutical, GEMoaB Monoclonals, and several others.
Non-muscle Invasive Bladder Cancer Market
DelveInsight's 'Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030' report deliver an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends, market drivers, market barriers and key companies involved such as FKD Therapies Oy, Ferring Pharmaceuticals, Merck, Viventia Bio, Sesen Bio, CG Oncology, ImmunityBio, Altor Biosciences, Theralase, and many others.
Checkpoint Inhibitor Refractory Cancer Market
DelveInsight's 'Checkpoint Inhibitor Refractory Cancer—Market Insights, Epidemiology, and Market Forecast—2030' report deliver an in-depth understanding of the Checkpoint Inhibitor Refractory Cancer, historical and forecasted epidemiology, market drivers, market barriers, unmet medical needs, and key companies including Bristol-Myers Squibb, AstraZeneca, Merck, Genentech/Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, and Pfizer, Bristol-Myers Squibb, Janssen Research and Development, LLC, Exicure, Inc., Evelo Biosciences, Inc./Merck Sharp & Dohme Corp, Eisai, Kartos Therapeutics, Exelixis, Immunity Bio, and many others.
DelveInsight's 'Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, emerging drugs like Cemiplimab, Durvalumab, Tisotumab vedotin, and key companies involved like Genentech/Roche, Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, and others
Intratumoral Cancer Therapies Market
DelveInsight's 'Intratumoral Cancer Therapies - Market Insights, Epidemiology and Market Forecast—2030' report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Takara Bio, NanOlogy, Istari Oncology, Moderna Therapeutics, Intensity Therapeutics, and several others.
Browse Through Our Blog Posts
- Showstoppers in Gastric Cancers - ASCO 2021
- Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
- Metastatic HER2-Positive Breast Cancer Infographic
- Pitfalls of Current Osteosarcoma Treatment Approaches
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article